CAJ | 학술논문

目的探讨18F-FDG PET-CT在前列腺癌复发、转移诊断中的价值.方法回顾性分析23例前列腺癌治疗后随访期间临床怀疑复发、转移患者的18F-FDG显像资料,同期常规显像检查结果,病理及临床随访结果.结果经病理及临床随访结果证实前列腺癌复发、转移者19例.PET-CT诊断为阳性者20例,其中1例盆腔脓肿、5例前列腺癌局部复发、8例盆腔淋巴结转移、1例全身多发淋巴结转移和5例骨转移;18F-FDG PET-CT诊断前列腺癌复发与转移的灵敏度为100%(19/19),特异度为75%(3/4),准确率为95%(22/23).内分泌治疗后前列腺特异性抗原水平较稳定及逐渐升高者共12例,PET-CT均准确显示.与B超、CT、骨显像相比,PET-CT可发现更多的病灶.结论 18F-FDG PET-CT对前列腺癌复发、转移的诊断有重要价值.
목적 탐토18F-FDG PET-CT재전렬선암복발、전이진단중적개치.방법 회고성분석23례전렬선암치료후수방기간림상부의복발、전이환자적18F-FDG현상자료,동기상규현상검사결과,병리급림상수방결과.결과 경병리급림상수방결과증실전렬선암복발、전이자19례.PET-CT진단위양성자20례,기중1례분강농종、5례전렬선암국부복발、8례분강림파결전이、1례전신다발림파결전이화5례골전이;18F-FDG PET-CT진단전렬선암복발여전이적령민도위100%(19/19),특이도위75%(3/4),준학솔위95%(22/23).내분비치료후전렬선특이성항원수평교은정급축점승고자공12례,PET-CT균준학현시.여B초、CT、골현상상비,PET-CT가발현경다적병조.결론 18F-FDG PET-CT대전렬선암복발、전이적진단유중요개치.
Objective To investigate the value of 18F-FDG PET-CT on patients with suspected prostate cancer recurrence and metastasis. Methods Retrospective analysis 23 patients with prostate cancer who were suspected to have tumor recurrence and metastasis during follow-up, underwent 18F-FDG PET-CT examination. 18F-FDG PET-CT results were compared with those of conventional images, as referred to histopathology or clinical follow-up. Results In total, 19 patients with recurrence and metastasis were confumed by histopathology or clinical follow-up. Twenty patients were found to have positive lesion by 18F-FDG PET-CT, including the pelic abscess (1case), prostate cancer local recurrence (5cases), lymph node metastases(8cases), multiple systemic lymph node metastasis(lcase)and bone metastases(5cases). The sensitivity of 18F-FDG PET-CT was 100% (19/19) in diagnosis carcinoma recurrence and metastasis, and the specificity and accuracy were 75% (3/4) and 95%(22/23). The levels of prostate specific antigen in 12 patients gradually increased after endocrine theraphy, and PET-CT could dipit this accurately. Compared with conventional images such as B mode ultrasonic, CT, bone imaging, 18F-FDG PET-CT could find more focus. Conclusion 18F-FDG PET-CT imaging is valuable in diagnosing recurrent and metastatic prostate cancer.